Long-Term Follow-up Study of ADVM-043
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03804021 |
Recruitment Status :
Completed
First Posted : January 15, 2019
Last Update Posted : March 31, 2022
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Alpha-1 Antitrypsin Deficiency | Genetic: ADVM-043 |
Study Type : | Observational |
Actual Enrollment : | 6 participants |
Observational Model: | Other |
Time Perspective: | Prospective |
Official Title: | Post-treatment Long-term Follow-up Study of ADVM-043 Gene Therapy in Alpha-1 Antitrypsin Deficiency |
Actual Study Start Date : | December 27, 2018 |
Actual Primary Completion Date : | December 6, 2021 |
Actual Study Completion Date : | December 6, 2021 |
Group/Cohort | Intervention/treatment |
---|---|
1
Patients who received ADVM-043 in a treatment protocol
|
Genetic: ADVM-043
Long term follow-up of subjects that received ADVM-043 |
- Type, frequency, severity, duration, and relationship to ADVM-043 of adverse events of interest and of serious adverse events related to ADVM-043 [ Time Frame: 2 years ]Safety was assessed by collection of severity and relatedness of Adverse Events to ADVM-043, Adverse Events of Interest and Serious Adverse Events related to ADVM-043
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Key Inclusion Criteria:
- The subject has A1AT deficiency and has previously received ADVM-043 gene therapy
Key Exclusion Criteria:
- The subject is unwilling or unable to participate in all required study evaluations in the long-term follow-up protocol
- The subject is participating in another investigational treatment protocol
- The subject is unable to understand the purpose and risks of the study or cannot provide a signed and dated informed consent form (ICF)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03804021
United States, Florida | |
University of Florida | |
Gainesville, Florida, United States, 32610 | |
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 |
Principal Investigator: | Charlton Strange, MD | Medical University of South Carolina, Charleston, SC, USA | |
Principal Investigator: | Mark Brantly, MD | University of Florida, Gainesville, FL, USA |
Responsible Party: | Adverum Biotechnologies, Inc. |
ClinicalTrials.gov Identifier: | NCT03804021 |
Other Study ID Numbers: |
ADVM-043-03 |
First Posted: | January 15, 2019 Key Record Dates |
Last Update Posted: | March 31, 2022 |
Last Verified: | March 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Alpha-1 Antitrypsin Deficiency alpha1-antitrypsin deficiency alpha 1-antitrypsin deficiency alpha1AT A1AT ADVM-043 AAVrh.10halpha1AT AAVrh.10hA1AT |
Gene transfer vector Gene therapy Lung disease Emphysema COPD ADVANCE study Long Term Follow Up |
Alpha 1-Antitrypsin Deficiency Liver Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases |
Genetic Diseases, Inborn Subcutaneous Emphysema Emphysema Pathologic Processes |